CAMBRIDGE, Mass., Nov. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American Association for Cancer Research (AACR)/National Cancer Institute (NCI)/European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics taking place November 12-16, 2011, in San Francisco, California.
(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO )
MM-398
MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan. The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer. PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02.
Title: Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan Poster Session: Topoisomerase Inhibitors Number: C207 Date/Time: Tuesday, Nov 15, 2011, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Center West | |
MM-121
MM-121 is a monoclonal antibody designed to block signaling through the ErbB3 (HER3) receptor. MM-121, in partnership with Sanofi, is in clinical development in patients with breast, lung and ovarian cancer.
Title: Targeting ErbB3 (HER3) and EGFR in Lung Cancer Patients: A Phase I Trial of MM-121 in Combination with Erlotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Poster Session: Clinical Trials 3 Number: C27 Date/Time: Tuesday, Nov 15, 2011, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Center West | |
MM-111
MM-111 is a novel bispecific antibody against ErbB3 (HER3), using an ErbB2 (HER2) targeting arm to enhance avidity and inhibition.
Title: Optimization of MM-111 and lapatinib dosing regimens using mathematical modeling and quantitative biology Poster Session: Pharmacokinetics and Pharmacodynamics 3 Number: C118 Date/Time: Tuesday, Nov 15, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Convention Center West | |
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin designed to target ErbB2 (HER2) overexpressing cancer cells, while limiting uptake into non-target cells.
Title: HER2-targeted liposomal doxorubicin, MM-302, has a favorable cardiosafety profile in preclinical models Poster Session: Novel Assay Technology Number: C90 Date/Time: Tuesday, Nov 15, 2011, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Center West | |
MM-151
MM-151 is a mixture of three fully human monoclonal antibodies directed against distinct non-overlapping epitopes in EGFR.
Title: Elucidating mechanisms of action of MM-151, a mixture of three human antibody antagonists targeting EGFR Poster Session: Therapeutic Agents: Biological 1 Number: A210 Date/Time: Sunday, Nov 13, 2011, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Center West | |
Title: Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic Poster Session: EGFR / Her2 Number: A144 Date/Time: Sunday, Nov 13, 2011, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Center West | |
MM-141
MM-141 is a comprehensive IGF-1R signaling inhibitor that is designed to address the redundancies that occur in tumors where both IGF-1R and ErbB3 (HER3) are activated, an approach intended to improve patient response by blocking survival signaling promoted by two separate pathways.
Title: Therapeutically targeting redundant, growth factor-induced pro-survival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3 (HER3) Poster Session: Therapeutic Agents: Biological 2 Number: B205 Date/Time: Monday, Nov 14, 2011, 12:30 PM 2:30 PM Location: West Hall, Level One, Moscone Convention Center West | |
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.
Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com
SOURCE Merrimack Pharmaceuticals, Inc.
